MASP-2 Inhibitory Antibody Lectin Pathway Complement Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors, such as Eculizumab, target downstream molecules in the complement system, failing to inhibit the initiation steps of complement activation, which can lead to tissue damage in various disease states, and there is a need for effective inhibitors that can specifically target the initiation pathways to prevent adverse effects.
Innovation Solution
Development of a MASP-2 inhibitory antibody that specifically targets MASP-2, a key component of the lectin pathway, to inhibit MASP-2-dependent complement activation, thereby preventing microvascular endothelial cell injury and thrombus formation in conditions like atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If downstream complement inhibitors like Eculizumab are used to block C5, then complement-mediated tissue injury is reduced, but the initiation steps of complement activation remain uninhibited leading to continued tissue damage
Solution Approach 1:
The patent extracts and targets the specific initiation mechanism of complement activation through MASP-2 inhibition, separating this function from the overall complement system. By specifically blocking MASP-2 in the lectin pathway, the invention prevents the initiation of complement activation while preserving other pathways, thereby achieving more complete and reliable inhibition of harmful complement-mediated tissue injury.
Solution Approach 2:
The patent applies preliminary action by blocking MASP-2 at the initiation step of complement activation, before the cascade progresses to downstream effector molecules. This upstream inhibition prevents the formation of C3 convertase and subsequent amplification, providing more effective prevention of tissue damage compared to downstream C5 blockade alone.
2Object-affected harmful factors
If broad complement inhibition is applied to prevent tissue damage, then protective immune response is reduced, but pathogen clearance capability is maintained
Solution Approach 1:
The patent applies local quality by selectively inhibiting MASP-2 in the lectin pathway while leaving the classical and alternative pathways intact. This localized inhibition targets specific harmful complement activation without broadly suppressing the entire complement system, thereby maintaining immune defense capabilities through preserved pathways while preventing tissue damage through blocked lectin pathway activation.
Data Source
AI summary
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.